Sanofi SA (NYSE:SNY) Downgraded to “Hold” at BidaskClub
Sanofi SA (NYSE:SNY) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
Several other equities research analysts also recently issued reports on the stock. Argus increased their price objective on shares of Sanofi SA from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Zacks Investment Research raised shares of Sanofi SA from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Friday, June 2nd. Berenberg Bank downgraded shares of Sanofi SA from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. TheStreet raised shares of Sanofi SA from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi SA in a research report on Thursday, April 20th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $67.67.
Sanofi SA (SNY) traded up 0.06% during trading on Wednesday, reaching $47.83. 903,557 shares of the company’s stock traded hands. The firm’s 50 day moving average is $48.89 and its 200 day moving average is $44.55. The company has a market cap of $120.79 billion, a P/E ratio of 11.87 and a beta of 0.89. Sanofi SA has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi SA (NYSE:SNY) last issued its earnings results on Friday, April 28th. The company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The firm had revenue of $8.65 billion during the quarter, compared to the consensus estimate of $8.40 billion. The firm’s revenue was up 1.2% compared to the same quarter last year. Analysts anticipate that Sanofi SA will post $3.15 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Sanofi SA (NYSE:SNY) Downgraded to “Hold” at BidaskClub” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/05/sanofi-sa-nysesny-downgraded-to-hold-at-bidaskclub.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Dodge & Cox acquired a new position in shares of Sanofi SA during the fourth quarter valued at approximately $2,770,485,000. Wells Fargo & Company MN boosted its position in shares of Sanofi SA by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares during the last quarter. Global Financial Private Capital LLC acquired a new position in shares of Sanofi SA during the first quarter valued at approximately $35,034,000. Karp Capital Management Corp acquired a new position in shares of Sanofi SA during the first quarter valued at approximately $26,174,000. Finally, Bank of America Corp DE boosted its position in shares of Sanofi SA by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after buying an additional 572,652 shares during the last quarter. Institutional investors and hedge funds own 9.84% of the company’s stock.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.